Table of Contents
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
• Market outline

PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast

PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 08: PIPELINE LANDSCAPE

PART 09: MARKET SEGMENTATION BY CATEGORY
• Segmentation by category
• Comparison by category
• Global immunosuppressants market
• Global immuno boosters market
• Market opportunity by category

PART 10: MARKET SEGMENTATION BY INDICATION
• Autoimmune diseases
• Oncology
• Organ transplantation
• Others

PART 11: CUSTOMER LANDSCAPE

PART 12: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Immunology market in Americas
• Immunology market in EMEA
• Immunology market in APAC
• Market opportunity

PART 13: DECISION FRAMEWORK

PART 14: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges

PART 15: MARKET TRENDS
• Significant pipeline
• Collaborations and partnerships for R&D
• Advanced diagnostic technologies

PART 16: VENDOR LANDSCAPE
• Overview
• Landscape disruption

PART 17: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie
• Amgen
• F. Hoffmann-La Roche
• Johnson & Johnson

PART 18: APPENDIX
• List of abbreviations

[List of Exhibits]
Exhibit 01: Parent market
Exhibit 02: Global immunology market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition: Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global immunology market 2017-2022 ($ billions)
Exhibit 09: Global immunology market: Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition: Five forces 2017
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Key clinical trials
Exhibit 20: Global immunology market by category 2017-2022 (%)
Exhibit 21: Comparison by category
Exhibit 22: Immunosuppressant drugs
Exhibit 23: Global immunosuppressants market 2017-2022 ($ billions)
Exhibit 24: Global immunosuppressants market: Year-over-year growth 2018-2022 (%)
Exhibit 25: Classification of immuno boosters
Exhibit 26: Global immuno boosters market 2017-2022 ($ billions)
Exhibit 27: Global immuno boosters market: Year-over-year growth 2018-2022 (%)
Exhibit 28: Market opportunity by category
Exhibit 29: Brief history of immuno-oncology
Exhibit 30: Stages of anti-tumor immune response
Exhibit 31: Customer landscape
Exhibit 32: Global immunology market by geography 2017-2022 (%)
Exhibit 33: Regional comparison
Exhibit 34: Immunology market in Americas 2017-2022 ($ billions)
Exhibit 35: Immunology market in Americas: Year-over-year growth 2018-2022 (%)
Exhibit 36: Top three countries in Americas
Exhibit 37: Immunology market in EMEA 2017-2022 ($ billions)
Exhibit 38: Immunology market in EMEA: Year-over-year growth 2018-2022 (%)
Exhibit 39: Top three countries in EMEA
Exhibit 40: Immunology market in APAC 2017-2022 ($ billions)
Exhibit 41: Immunology market in APAC: Year-over-year growth 2018-2022 (%)
Exhibit 42: Top three countries in APAC
Exhibit 43: Market opportunity
Exhibit 44: Rise in organ transplantation in US 2015-2016
Exhibit 45: Organ transplantation by donor type 2016
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: AbbVie: Vendor overview
Exhibit 52: AbbVie: Business segments
Exhibit 53: AbbVie: Organizational developments
Exhibit 54: AbbVie: Geographic focus
Exhibit 55: AbbVie: Segment focus
Exhibit 56: AbbVie: Key offerings
Exhibit 57: Amgen: Vendor overview
Exhibit 58: Amgen: Business segments
Exhibit 59: Amgen: Organizational developments
Exhibit 60: Amgen: Geographic focus
Exhibit 61: Amgen: Segment focus
Exhibit 62: Amgen: Key offerings
Exhibit 63: F. Hoffmann-La Roche: Vendor overview
Exhibit 64: F. Hoffmann-La Roche: Business segments
Exhibit 65: F. Hoffman-La Roche: Organizational developments
Exhibit 66: F. Hoffmann-La Roche: Geographic focus
Exhibit 67: F. Hoffmann-La Roche: Segment focus
Exhibit 68: F. Hoffmann-La Roche: Key offerings
Exhibit 69: Johnson & Johnson: Vendor overview
Exhibit 70: Johnson & Johnson: Business segments
Exhibit 71: Johnson & Johnson: Organizational developments
Exhibit 72: Johnson & Johnson: Geographic focus
Exhibit 73: Johnson & Johnson: Segment focus
Exhibit 74: Johnson & Johnson: Key offerings